(Q37173942)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19276275%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

review article

1 reference

title

Randomized phase II designs (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19276275%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19276275%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

author name string

Larry Rubinstein

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19276275%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

John Crowley

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19276275%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Percy Ivy

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19276275%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Michael Leblanc

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19276275%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

language of work or name

English

0 references

publication date

10 March 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19276275%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

published in

Clinical Cancer Research

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19276275%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

volume

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19276275%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19276275%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

page(s)

1883-1890

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19276275%20AND%20SRC:MED&resulttype=core&format=json

Effective incorporation of biomarkers into phase II trials

23 January 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3774021

Alternate endpoints for screening phase II studies.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3774021

Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3774021

Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3774021

A review of phase 2-3 clinical trial designs

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3774021

Proposal for the use of progression-free survival in unblinded randomized trials

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3774021

The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3774021

Objective responses in patients with malignant melanoma or renal cell cancer in early clinical studies do not predict regulatory approval

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3774021

Clinical trial designs for the early clinical development of therapeutic cancer vaccines

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3774021

Clinical trial designs for cytostatic agents: are new approaches needed?

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3774021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3774021

False positive rates of randomized phase II designs

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3774021

Interim futility analysis with intermediate endpoints

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3774021

Design issues of randomized phase II trials and a proposal for phase II screening trials

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3774021

Planned versus attained design in phase II clinical trials

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3774021

An efficient design for phase III studies of combination chemotherapies.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3774021

Calibrated phase II clinical trials in oncology

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3774021

Optimal two-stage designs for phase II clinical trials

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3774021

Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer.

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3774021

Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3774021

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3774021

Conditional power calculations for clinical trials with historical controls.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3774021

Some design issues in trials of microbicides for the prevention of HIV infection

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3774021

Selection designs for pilot studies based on survival.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3774021

Randomized discontinuation design: application to cytostatic antineoplastic agents

3 September 2018

1 reference

12 December 2020

Randomized phase II clinical trials

1 reference

12 December 2020

Design and conduct of phase II studies of targeted anticancer therapy: recommendations from the task force on methodology for the development of innovative cancer therapies (MDICT)

1 reference

12 December 2020

A simple approximation for calculating sample sizes for comparing independent proportions

1 reference

12 December 2020

Comparing an experimental agent to a standard agent: relative merits of a one-arm or randomized two-arm Phase II design

1 reference

12 December 2020

Planning the duration of a comparative clinical trial with loss to follow-up and a period of continued observation

1 reference

12 December 2020

Non-randomised phase II trials of drug combinations: often meaningless, sometimes misleading. Are there alternative strategies?

1 reference

12 December 2020

Phase II trials in the EORTC. The Protocol Review Committee, the Data Center, the Research and Treatment Division, and the New Drug Development Office. European Organization for Research and Treatment of Cancer

1 reference

12 December 2020

Evaluation of randomized discontinuation design

1 reference

12 December 2020

Randomized phase II trials: what does randomization gain?

1 reference

12 December 2020

Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis

1 reference

12 December 2020

Small randomized trials

1 reference

12 December 2020

10.1158/1078-0432.CCR-08-2031

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19276275%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19276275%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

PubMed publication ID

19276275

1 reference